Actualización en la terapia de la hepatitis C. Nuevos fármacos, monitorización de la respuesta y resistencias

Chueca Porcuna, Natalia; Álvarez Estévez, Marta; Parra Ruiz, Jorge; Hernández Quero, José; García García, Federico.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 31(supl.1): 40-47, feb. 2013. ilus, tab, graf
Artículo en Español | IBECS (España) | ID: ibc-179599

Documentos relacionados

  1. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
  2. New antivirals exploit viral feedback tricks for a cure without resistance.
  3. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
  4. New antivirals and drug resistance.
  5. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
  6. Understanding the Impact of Resistance to Influenza Antivirals.
  7. Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges.
  8. Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.
  9. SLiM-binding pockets: an attractive target for broad-spectrum antivirals.
  10. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.